PLSE
HealthcarePulse Biosciences, Inc. · Medical - Instruments & Supplies · $2B
What is Pulse Biosciences, Inc.?
Pulse Biosciences is a small-cap bioelectric medicine company focused on a proprietary cell-targeting technology. Headquartered in Hayward, California, it is working to bring a novel energy-based treatment platform to the medical device market.
Pulse Biosciences develops and commercializes the CellFX System, a software-enabled console platform that delivers ultra-short electrical pulses to selectively clear targeted cells without generating heat or damaging surrounding tissue. The underlying technology — Nano-Pulse Stimulation — is designed to treat a range of medical conditions by exploiting the biological response of cells to nanosecond-duration electrical energy. Revenue is generated through capital equipment placements and related consumables.
The company was incorporated in 2014 and rebranded as Pulse Biosciences in December 2015.
- CellFX System — tunable, console-based energy delivery platform
- Nano-Pulse Stimulation (NPS) technology for non-thermal cell targeting
- Software-enabled treatment protocols for multiple medical conditions
- Consumable accessories supporting the CellFX platform
Is PLSE a Good Stock to Buy?
UQS Score rates PLSE as Poor overall, reflecting significant challenges across most of its fundamental pillars.
The one relative bright spot in PLSE's profile is its Risk pillar, which is rated Good — suggesting the balance sheet carries a manageable near-term risk profile, which is notable for an early-stage medical device company still building commercial traction.
Quality, Moat, and Growth are all rated Weak, pointing to limited revenue scale, an unproven competitive position, and an uncertain growth trajectory. Valuation is rated Elevated, meaning the current market price appears to price in optimism that the fundamentals have not yet supported.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does PLSE pay dividends?
No — Pulse Biosciences, Inc. does not currently pay a dividend.
Pulse Biosciences does not pay a dividend. As an early-stage company still investing heavily in technology development and commercialization, capital is directed toward building out the CellFX platform rather than returning cash to shareholders. Income-focused investors should factor this into their assessment.
When does PLSE report earnings?
Pulse Biosciences reports earnings on a quarterly cadence, consistent with standard US-listed public company requirements.
Given the Weak ratings across Quality and Growth pillars, recent reporting periods have reflected the challenges typical of a pre-scale medical device company — limited commercial revenue and ongoing investment in platform development. Progress on CellFX adoption is a key metric to watch each quarter.
For the most recent quarter's results and guidance, visit Pulse Biosciences' investor relations page directly.
PLSE Price History
+32.9% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Pulse Biosciences, Inc.?
Based on Pulse Biosciences, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
PLSE Long-term Outlook
The fundamental outlook for PLSE is uncertain. With Growth and Quality both rated Weak, the near-term trajectory depends heavily on whether the CellFX platform gains meaningful clinical and commercial adoption. The Good Risk rating provides some reassurance that the company is not in immediate financial distress, but the Elevated Valuation rating suggests the market may already be pricing in a recovery that has yet to materialize in the fundamentals.
Growth drivers
- Broader clinical adoption of the CellFX System across new treatment indications
- Expansion of the installed base driving recurring consumable revenue
- Potential partnerships or licensing arrangements for the NPS technology platform
Key risks
- Continued weak revenue generation could pressure the balance sheet over time
- Elevated valuation leaves limited margin of safety if commercialization stalls
- Competitive pressure from established energy-based medical device companies
PLSE vs Peers
Pulse Biosciences operates in the energy-based medical device space alongside several companies with more established commercial footprints.
AtriCure focuses on surgical ablation solutions for atrial fibrillation, giving it a more established commercial presence in cardiac surgery compared to PLSE's early-stage platform.
NovoCure applies electric fields to disrupt cancer cell division, representing a distinct but conceptually adjacent bioelectric approach with a more advanced commercial and clinical track record.
Kestra develops wearable cardioverter defibrillators, competing in the broader energy-based medical device market with a different clinical application and customer base.
Frequently Asked Questions
What does Pulse Biosciences do?
Pulse Biosciences develops the CellFX System, a platform that uses Nano-Pulse Stimulation technology to deliver ultra-short electrical pulses to targeted cells. The goal is to clear unwanted cells non-thermally — without heat — while leaving surrounding tissue intact. The company is working to apply this technology across multiple medical conditions.
Does PLSE pay dividends?
No, Pulse Biosciences does not currently pay a dividend. The company is in an early commercialization phase and directs available capital toward developing and expanding its CellFX platform rather than distributing cash to shareholders.
When does PLSE report earnings?
Pulse Biosciences follows a standard quarterly earnings cadence for US-listed companies. Specific upcoming dates are not covered by our data source — check the company's investor relations page for the current reporting schedule.
Is PLSE a good stock to buy?
UQS Score rates PLSE as Poor overall. The Quality, Moat, and Growth pillars are all rated Weak, and Valuation is rated Elevated. The Risk pillar is the one area rated Good. Investors should weigh these factors carefully against their own risk tolerance and investment goals.
Is PLSE overvalued?
The UQS Valuation pillar for PLSE is rated Elevated, suggesting the current market price reflects optimism that has not yet been validated by the company's fundamental performance. This is a meaningful consideration for investors evaluating entry points.
How does PLSE compare to its competitors?
Compared to peers like AtriCure, NovoCure, and Kestra Medical Technologies, Pulse Biosciences is at an earlier stage of commercialization. Its NPS technology is differentiated, but it lacks the established revenue base and clinical track record of more mature energy-based medical device companies.
What is PLSE's market cap bracket?
Pulse Biosciences is classified as a small-cap company. This places it in a category where liquidity can be lower and volatility higher than large- or mega-cap peers, which is relevant context for position sizing and risk management.
Who founded Pulse Biosciences?
The company was originally incorporated in 2014 under the name Electroblate, Inc. before rebranding as Pulse Biosciences in December 2015. Detailed founding history and leadership background are available through the company's public filings and investor relations materials.
Is PLSE a long-term quality investment?
As a long-term quality indicator, the UQS Score rates PLSE as Poor. The Weak ratings across Quality, Moat, and Growth pillars suggest the company has not yet established the durable fundamentals typically associated with long-term compounders. The platform's potential remains speculative at this stage.
What is the main competitive advantage of Pulse Biosciences?
Pulse Biosciences' potential advantage lies in its proprietary Nano-Pulse Stimulation technology, which targets cells non-thermally in a way that differs from conventional energy-based treatments. However, the UQS Moat pillar is rated Weak, reflecting that this advantage has not yet translated into a defensible commercial position.
What sector does PLSE belong to?
Pulse Biosciences operates in the Healthcare sector, specifically within the medical devices and bioelectric medicine space. Investors can explore other [Healthcare sector stocks](/sector/healthcare) on the UQS Score platform for broader context.
Unlock Full PLSE Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access full financial metrics and trend data
- ✓Compare PLSE against sector peers side by side
- ✓See valuation and risk flags in detail
- ✓Track score changes over time with Pro alerts
Pro Analysis
PLSE — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 16, 2026 | 21.2 | 0.0 | 14.0 | 37.9 | 67.5 | 0.0 | +0.2 |
| Apr 2, 2026 | 21.0 | 0.0 | 14.0 | 37.9 | 65.9 | 0.0 | — |
PLSE — Pillar Breakdown
Quality
— 0.0/100 (25%)Pulse Biosciences, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 37.9/100 (20%)Pulse Biosciences, Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 67.5/100 (15%)Pulse Biosciences, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Pulse Biosciences, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 14/100 (25%)Pulse Biosciences, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for PLSE.
Score Composition
Financial Data
More Stock Analysis
How is the PLSE UQS Score Calculated?
The UQS (Unified Quality Score) for Pulse Biosciences, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Pulse Biosciences, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Pulse Biosciences, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.